Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3410639 | 0.88 | ALDH1A1 (0.42) | ALDH1A1PIK3CDCA12CA2CA3 | |
| SCHEMBL29580442 | 0.85 | CA12 (0.44) | ALDH1A1PIK3CDCA12CA2CA3 | |
| SCHEMBL15865606 | 0.85 | CA12 (0.44) | ALDH1A1PIK3CDCA12CA2CA3 | |
| SCHEMBL29580486 | 0.85 | CA12 (0.44) | ALDH1A1PIK3CDCA12CA2CA3 | |
| SCHEMBL172303 | 0.84 | SIGMAR1 (0.38) | PIK3CDSIGMAR1 | |
| SCHEMBL18251199 | 0.84 | GGPS1 (0.38) | ALDH1A1 | |
| SCHEMBL12797125 | 0.82 | GGPS1 (0.46) | — | |
| SCHEMBL20028367 | 0.82 | SIGMAR1 (0.41) | PIK3CDSIGMAR1 | |
| SCHEMBL26628635 | 0.81 | SIGMAR1 (0.31) | SIGMAR1CA12CA2CA3CA4 | |
| SCHEMBL24673520 | 0.80 | SIGMAR1 (0.44) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240206470-A1 | VOLATILE APPLICATIONS AGAINST PATHOGENS | AGROFRESH INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-11813260-B1 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2023-11-14 | — | — | US | disclosed |
| US-11813259-B2 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230293706-A1 | Multicomponent Delivery Systems for Polyanionic Cargo Compound Delivery | MEDICI THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2023141576-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS | POSEIDA THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| US-11701434-B2 | Tertiary amino lipidated cationic peptides for nucleic acid delivery | NUTCRACKER THERAPEUTICS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| EP-4201936-A1 | HETEROAROMATIC RING COMPOUND AS RET KINASE INHIBITOR, AND PREPARATION AND USE THEREOF | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (CN) | 2023-06-28 | — | — | EP | disclosed |
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (US) | 2023-05-11 | — | — | US | disclosed |
| US-20210101875-A1 | AMINOALCOHOL LIPIDOIDS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-04-08 | — | — | US | disclosed |
| US-20200361896-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2020-11-19 | — | — | US | disclosed |
| US-20140154208-A1 | Novel [N-Me-4-hydroxyleucine]-9-Cyclosporin Analogues for Treatment and Prevention of Hepatitis C Infection | ENANTA PHARMACEUTICALS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-8648092-B2 | Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applications | MEI Pharma (US) | 2014-02-11 | — | — | US | disclosed |
| US-8309552-B2 | Immunomodulating heterocyclic compounds | MEDIGENE AG (DE) | 2012-11-13 | — | — | US | disclosed |
| US-8188132-B2 | Linked dibenzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20120076756-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2012-03-29 | — | — | US | disclosed |
| US-20110294869-A1 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | TRAVERSA THERAPEUTICS, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-20100331234-A1 | AMINOALCOHOL LIPIDOIDS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-10-14 | — | — | US | disclosed |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
| US-20090312334-A1 | Immunomodulating Heterocyclic Compounds | MEDIGENE LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140154208-A1 | Novel [N-Me-4-hydroxyleucine]-9-Cyclosporin Analogues for Treatment and Prevention of Hepatitis C Infection | HAVCR2, CHP1, CCL5 | ALDH1A1 3490/4885PIK3CD 2601/4885SIGMAR1 515/4885 |
| US-11813259-B2 | Benzamide compounds | MKI67, TMBIM6, HDAC1 | ALDH1A1 81/4885PIK3CD 2496/4885SIGMAR1 3721/4885 |
| US-11813260-B1 | Benzamide compounds | MKI67, TMBIM6, HDAC1 | ALDH1A1 81/4885PIK3CD 2496/4885SIGMAR1 3721/4885 |
| US-20230293706-A1 | Multicomponent Delivery Systems for Polyanionic Cargo Compound Delivery | MTREX, EXOSC5, KPNA6 | ALDH1A1 4262/4885PIK3CD 1443/4885SIGMAR1 2030/4885 |
| US-20120076756-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | ALDH1A1 201/4885PIK3CD 601/4885SIGMAR1 857/4885 |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | ALDH1A1 365/4885PIK3CD 739/4885SIGMAR1 1216/4885 |
| US-20110294869-A1 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | POLN, SARNP, NCL | ALDH1A1 4308/4885PIK3CD 1454/4885SIGMAR1 2018/4885 |
| US-20240206470-A1 | VOLATILE APPLICATIONS AGAINST PATHOGENS | OXA1L, VAPB, TIAL1 | ALDH1A1 1500/4885PIK3CD 4780/4885SIGMAR1 950/4885 |
| US-20090312334-A1 | Immunomodulating Heterocyclic Compounds | CD40, CD40LG, NGFR | ALDH1A1 2526/4885PIK3CD 3492/4885SIGMAR1 846/4885 |
| US-20210101875-A1 | AMINOALCOHOL LIPIDOIDS AND USES THEREOF | PHOSPHO1, PNMT, AASDHPPT | ALDH1A1 568/4885PIK3CD 429/4885SIGMAR1 2319/4885 |
| US-11701434-B2 | Tertiary amino lipidated cationic peptides for nucleic acid delivery | LNPEP, SLC7A1, APLNR | ALDH1A1 4814/4885PIK3CD 2115/4885SIGMAR1 929/4885 |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | EIF2AK2, NSUN2, ZC3HAV1 | ALDH1A1 287/4885PIK3CD 736/4885SIGMAR1 2209/4885 |
| US-20200361896-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, BMI1 | ALDH1A1 1093/4885PIK3CD 2096/4885SIGMAR1 3022/4885 |
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | HAVCR2, HMBS, VHL | ALDH1A1 172/4885PIK3CD 2759/4885SIGMAR1 2841/4885 |
| US-20100331234-A1 | AMINOALCOHOL LIPIDOIDS AND USES THEREOF | PHOSPHO1, PNMT, AASDHPPT | ALDH1A1 568/4885PIK3CD 429/4885SIGMAR1 2319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.